What We Do01Platform02Why Mycopharms03Who We Serve04Testimonials05Team06Contact07Get Started →
Generative ChemistryFungal GenomicsDrug Discovery

Unlock the hidden chemistry of fungi.

Generative AI that models millions of molecular structures derived from rare fungi — discovering novel chemical pathways for next-generation antibiotics and specialized therapeutics.

4.2M
Molecules modeled
842
Novel compounds identified
94%
Synthesis success rate
Discovery Engine · LiveLive
O N MP-8472C₂₄H₃₂N₄O₆
Compound MP-8472Binding 8.4 kcal/mol
Nature’s Pharmacy, Decoded by AI

1.5 billion years of chemical defense

We are just learning to read the language.

The Challenge

Fungi produce some of the most potent bioactive compounds known to science — penicillin, statins, immunosuppressants. But less than 5% of the estimated 5.1 million fungal species have been chemically characterized. Manual discovery is impossibly slow.

The Mycopharms Solution

Our generative AI models millions of molecular structures derived from fungal genomes — predicting novel chemical pathways for antibiotics and specialized therapeutics. We identify compounds with high binding affinity, low toxicity, and feasible synthesis routes — then validate them in silico before your lab ever touches a petri dish.

4.2M Molecules
842 Novel Compounds
94% Synthesis Rate
Fungal Genomes
→
AI Generation
→
Novel Therapeutics
The Fungal Discovery AI Stack

Four AI layers from genome to lead compound

Fungal genomics, transformed into pharmaceutical breakthroughs.

01

Generative Molecular Design

Variational autoencoders and transformers generate millions of novel molecular structures based on fungal biosynthetic gene clusters — exploring chemical space no human chemist could map.

Generative AI
02

Target Binding Prediction

Deep learning models predict binding affinity to specific protein targets (bacterial ribosomes, viral proteases, cancer kinases) — prioritizing compounds most likely to succeed.

Molecular Docking
03

Synthesis Route Optimization

AI evaluates synthetic accessibility — predicting viable chemical pathways and identifying required precursors, catalysts, and reaction conditions before lab synthesis begins.

Retrosynthesis
04

Toxicity & ADMET Prediction

Machine learning predicts absorption, distribution, metabolism, excretion, and toxicity — filtering out compounds likely to fail in clinical trials.

ADMET · Safety
Live — Mycopharms Discovery Engine

Novel compound MP-8472, scored in silico

LiveNovel Compound · MP-8472AI confidence 94.8%
Binding affinity
8.4kcal/mol
Synthesis score
87/100
Drug-likeness
92%
Toxicity risk
Low
Compound profile
FormulaC₂₄H₃₂N₄O₆
Target selectivityHigh
Patent noveltyNovel
Synthesis feasibility78%
Discovered compounds
MP-8472 — Antibiotic
Penicillium rubens · Novel
94%
MP-2917 — Antifungal
Amanita muscaria · Novel
91%
MP-1034 — Antiviral
Cordyceps militaris · Novel
88%
MP-7756 — Anticancer
Ganoderma lucidum · Novel
86%
MP-5512 — Immunomodulator
Hericium erinaceus · Novel
83%
Synthesis feasibility 78%
AI-validated retrosynthesis
The Drug Discovery Impact

Real outcomes from pharmaceutical R&D labs

Measured results from labs using the platform.

4.2M

Molecular structures modeled from fungal genomes

842

Novel compounds identified with therapeutic potential

94%

Synthesis success rate for AI-predicted pathways

6.4x

Faster discovery timeline vs. traditional screening

“Fungi have been evolving chemical defenses for 1.5 billion years. We’re just learning to read the language.”

Who We Serve

Built for pharmaceutical R&D

Mycopharms empowers every stakeholder in the drug discovery ecosystem.

Pharmaceutical R&D Labs

Accelerate antibiotic and therapeutic discovery with generative AI and in silico validation.

Biotech Startups

Build a pipeline of novel compounds without the cost of massive high-throughput screening.

Academic Research

Explore fungal chemical diversity for fundamental research and publication.

Contract Research Orgs

Offer AI-powered fungal compound discovery as a differentiated service to clients.

Testimonials

What scientists say

Trusted by leading pharmaceutical research teams worldwide.

★★★★★
Mycopharms identified a novel antibiotic scaffold from an obscure Penicillium species that our traditional screening missed entirely. It’s now our lead compound for MRSA.
Dr. Obi Mark
Head of Antibiotic Discovery, Merck Research Labs
★★★★★
We went from idea to validated lead compound in 6 months — a process that normally takes 3-4 years. The retrosynthesis AI is remarkably accurate.
Dr. Martha John
VP of Discovery Chemistry, Genentech
★★★★★
The ADMET predictions saved us from pursuing dozens of dead-end compounds. We now prioritize only candidates with real clinical potential.
Dr. Mikel Otanko
Director of Pharmacology, Novartis
Our Team

The fungal chemistry team

Mycologists, computational chemists, and AI researchers united to unlock nature’s pharmacy.

Dr.

Dr. Nabi Marwa

CEO & Co-Founder

Mycologist and natural products chemist with 15+ years in fungal secondary metabolites.

Dr.

Dr. Samuel Chuks

CTO & Co-Founder

AI/ML Ph.D. specializing in generative chemistry and molecular property prediction.

Dr.

Dr. Mary Clement

Head of Computational Chemistry

Molecular dynamics and docking expert. Built the binding prediction models behind Mycopharms.

David Uche

VP of Product

Product leader with deep experience in scientific software and drug discovery platforms.

Contact

Ready to discover novel therapeutics?

Tell us about your discovery goals, and we’ll show you how Mycopharms can help.

Email
Nabi@mycopharms.com
Address
Gbessa village near Sauka District Airport road, FCT abuja, Abuja, Federal Capital Territory, NG
Custom compound synthesisNeed a specific molecular scaffold or novel fungal compound synthesized? Our chemists and AI team can design and validate a custom synthesis route.
Get Started

Start discovering novel therapeutics today

Deploy Mycopharms in your R&D workflow in days. Start exploring fungal chemical space with generative AI.

1

Submit

Provide your target protein, therapeutic area, and any known fungal genomes of interest.

2

Generate

Our AI models millions of molecular structures and predicts binding, synthesis, and safety.

3

Validate

Receive ranked lead compounds with synthesis routes — ready for lab validation.

Start Your Free Trial